Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Cell Culture market research products provide analysis of the latest trends, developments and market data for this industry. Research information will help you make informed business decisions.

older | 1 | 2 | 3 | (Page 4) | 5 | 6 | .... | 17 | newer

    0 0

    The 2013-2018 Outlook for Cell/tissue Culture Supplies in the United States This econometric study covers the latent demand outlook for cell/tissue culture supplies across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it’s state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for cell/tissue culture supplies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all

    0 0

    The 2013-2018 Outlook for Cell/tissue Culture Sera in the United States This econometric study covers the latent demand outlook for cell/tissue culture Sera across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it’s state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for cell/tissue culture Sera. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all

    0 0

    The 2013-2018 Outlook for Cell/tissue Culture Reagents in the United States This econometric study covers the latent demand outlook for cell/tissue culture reagents across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it’s state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for cell/tissue culture reagents. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all

    0 0

    The 2013-2018 Outlook for Cell and Tissue Culture Supplies in the United States This econometric study covers the latent demand outlook for cell and tissue culture supplies across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it’s state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for cell and tissue culture supplies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable

    0 0

    Conference Documentation: Cell Based Assays Special Managers Rate £799, limited availability. Book online today Following on from our hugely successful Cell-Based Assays conference in 2012 SMi will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.   Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years. There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.

    0 0
  • 10/31/13--22:00: Marine Biotechnology
  • Marine Biotechnology This report analyzes the worldwide markets for Marine Biotechnology in US$ Million. The Global market is further analyzed by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. Major End-Use Applications also analyzed for the global market include Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 99 companies including many key and niche players such as - Aker BioMarine AS Aqua Bio Technology ASA Aquapharm Biodiscovery Ltd. CP Kelco Cyanotech Corp. Nutrex Hawaii Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as

    0 0

    High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics), by Apllications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018 “Technological Advancements and Flourishing Outsourcing Industry Likely to Propel the Growth of the Global High Throughput Screening (HTS) Market” In this report, the global high throughput screening (HTS) market has been segmented on the basis of technology, products, applications, end users, and geography. The label-free technology market is expected to grow at the highest CAGR of 11.1% from 2013 to 2018. This technology offers the direct detection ability, which was not possible with cell-based assays. Moreover, this technology helps in the reduction of drug failure rate due to toxicity and is applicable for a majority of drug classes. In the HTS applications market, the target identification segment accounted for the largest share in 2013. The large share of this segment can be attributed to factors such as the availability of large compound libraries, presence of well-equipped HTS laboratories, and technological advancements. Large pharmaceutical and biotechnology companies are investing heavily in automation of HTS laboratories and are also entering into

    0 0

    Gene Expression Reagent Trends Gene Expression refers to the production of functional products, most commonly proteins, using information saved in a specific gene. Gene expression is a key process undertaken by all life forms, including unicellular as well as multicellular organisms, primarily for generating their macromolecular machinery. The report analyzes and presents an overview of Gene Expression Reagents market worldwide. Supported with 3 market data tables, the report provides a review of global market trends, and various strategic industry activities of major companies witnessed by the industry over the last few years. In addition, 30 companies operating in the Gene Expression Reagents arena worldwide including Affymetrix Inc., Agilent Technologies Inc., GE Healthcare, Illumina Inc., Life Technologies Corporation, Thermo Fisher Scientific Inc., and others are profiled. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version

    0 0

    In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular), Method (Cellular Assay, Ex vivo, In Silico) - Global Forecast to 2018 Attributed to the support offered by the European government, the in vitro toxicology testing market in Europe was the largest in 2013 and is expected to hold the same stance by 2018 There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in experimentation is becoming dearer, primarily due to the costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues including concerns for animal welfare. Moreover the rates of drug attrition have also risen in recent years due to lesser availability of data on the toxicity profiles of the candidates that are under development process. To counteract these issues there has been a rise in the development of in vitro methods that are alternative to animal testing. A paradigm shift is observed towards emerging technologies such

    0 0

    Cell-based Assays: Technologies and Global Markets BCC Research estimates that the global market for cell-based assays will increase at a compound annual growth rate (CAGR) of 12.4% over the next five years to reach $15.2 billion in 2015 and $21.6 billion by 2018 from $12.1 billion in 2013. This report provides: An overview of the global market for cell-based assays available and currently used. Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018. Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery, and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use. Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand. Coverage of new technologies, trends, alliances, and mergers.

    0 0

    Protein Expression Market by Products (Expression Vector, Service, Reagent), Application (Industrial, Therapeutic), Expression Systems (Mammalian, Prokaryotic, Baculovirus, Yeast) & by End User (Pharmaceutical, Biotechnology, CRO) - Global Forecast to 2018 Protein expression denotes the presence and the abundance of one or more proteins in a cell or tissue. It forms an integral part of proteomic research as many commercially important proteins are produced downstream of protein expression. The protein expression market is expected to be driven by a number of factors. In the pharmaceutical sector, decline in the productivity of R&D and the sales drop expected by the upcoming patent cliff has resulted in intense research activities. Furthermore, the rise of the biologics market will increase research related to it, while the growth of the proteomics market will boost the protein expression market to a large extent. The intensity of research has increased in the pharmaceutical sector to compensate the lack of noteworthy results from R&D. Even though the budgets from R&D have increased over the years, the number of innovative technologies has not grown in tandem. In addition, biologics market is on the rise which will provide impetus to the research activities related to it. The growth of the proteomics industry

    0 0

    Cell-Based Assays: World Industry and Market Prospects 2014-2024 Cellular testing for pharma - new report showing technological trends and sales forecasts What's the future of technologies for screening cells? Now you get technological and commercial predictions there from 2014. Stay ahead, then, for data, helping your influence. So you explore developmental trends, sales results, opportunities, and revenue forecasting. That new study by visiongain shows you what's possible for cell-based tests and related applications to benefit drug discovery and development. So avoid missing out for pharma R&D tools. Instead find progress there, discovering expected trends, progress and gains. Read on to explore cell assaying technology, seeing how high its revenues can go. Forecasts and other analysis showing potential earnings from cell assays That updated study gives you sales predictions to 2024 at overall world, submarket, and national level. See what the future holds. For those drug discovery and development products you investigate where demand and money lie, seeing potential gains. There hear what's possible. And avoid struggles to find information. Besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. So you discover 51 tables, 48 charts, and three interviews with authorities in that industry. There

    0 0

    Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 2018 Label-free technology is rapidly gaining widespread acceptance as a drug discovery and life science research tool. Currently, the drug discovery process is based on target identification and screening for drug candidates. The label-free technologies are used for studying biomolecular interactions and eliminate the confounding effects of spatial interference, autofluorescent or quenching associated with use of labels. These technologies provide a rapid and real-time approach to both biochemical and cell-based assays which aid in new drug discovery. Since no labeling or reporter molecules are used for detection label-free detection offers higher sensitivity. Also, using the time-consuming and labor-intensive process of fluorescent, chemical, or radioactive labels has many disadvantages. As such, the acceptance of label-free technologies in biomolecular interaction analysis in drug discovery is growing. The increasing drug discovery initiatives by pharmaceutical companies and academic institutes will help to bolster the growth of label-free detection market in the forecast period. Furthermore, increasing R&D budgets of pharmaceutical companies coupled with decreasing R&D productivity have amplified the research activities in the pharmaceutical industry. This will

    0 0

    Cell-based Assays Market by Product [Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services], Application (Drug Discovery, ADMET), End-user (Pharmaceutical, CRO) - Global Forecast to 2018 The market for cell-based assays is driven by the preference over biochemical assays and animal models and the emergent 3D cell-based assay techniques in cell-based assays There has been a substantial rise in the costs to develop a new drug in recent years. This is specially observed when a new compound enters animal testing. The use of animals in experimentation is becoming dearer, due to limitations such as high costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues and legal issues associated with it. Moreover the traditional biochemical assays also posses many limitations. To counteract these issues there has been a paradigm shift towards the use of cell-based assays. The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and

    0 0

    Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth Factors, Serum Free Media), by Application (Cancer Research, Gene Therapy, Drug Development, Vaccine Production, Toxicity Testing) - Global Forecast to 2018 The report segments the cell culture market into two distinct market segments, namely, the cell culture equipment market and the cell culture media, sera, and reagents market. The segments of the cell culture equipment market included in this report are bio-safety cabinets, consumables, lab equipment, sterilization equipment, and storage equipment. The lab equipment segment consists of four subsegments, namely, cell counters, centrifuges, fermentors and bioreactors, and incubators. The storage equipment segment consists of two subsegments, namely, cryogenic storage and refrigerators and freezers. The segments of the cell culture media, sera, and reagents market included in this report are contamination detection kits, cryoprotective agents, lab reagents, media, serum, and other reagents. The lab reagents segment consists of four subsegments, namely, balanced salt solutions, buffers and chemicals, cell dissociation reagents, and supplements and growth factors. The media segment consists of three subsegments, namely, basal media, reduced serum media, and serum-free media. Cell culture has its applications in a large number of fields. On the basis

    0 0

    Press Release TechNavio Announces the Publication of its Research Report - Global Cell Culture Market 2014-2018 TechNavio recognizes the following companies as the key players in Global Cell Culture Market: Becton, Dickinson and Co., EMD Millipore, GE Healthcare, Lonza Group AG, Sigma Aldrich Corp., Thermo Fisher Scientific Inc., Advanced Instruments, Affymetrix, Athena, Atlanta Biologicals , Biological Industries, Bioreclamation , Bio-Techne , Biowest , Cell Culture Technologies, CellGenix, Corning Life Sciences, Ependrof, Gemini Bio-Products, InVitria , Irvine Scientific, J R Scientific, MP Biomedicals, Quality Biological, Selexis, Sera Lab, Synthecon, VWR International, WISENT, ZenBio Commenting on the report, an analyst from TechNavio’s team said: “Automated cell culture systems are instruments that mechanically support the growth and maintenance of cell culture. They allow production of optimum cells at a large scale to meet the needs of researchers in drug discovery and industries and biopharmaceutical companies. Cell culture automation systems are extensively used in mAb production, iPSC research, cryobanking, cell-based assays, and cellular expression systems as they save time and reduce contamination risk”According to the report, the Global Cell Culture market is driven by several factors. One of its major drivers is the increased demand for biopharmaceuticals. Popularity of biopharmaceuticals has increased because of its high efficacy

    0 0

    Cell and Tissue Culture Supplies This report analyzes the worldwide markets for Cell and Tissue Culture Supplies in US$ Thousands by the following Product Segments: Media, Sera, and Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 67 companies including many key and niche players such as - Affymetrix, Inc. AMRESCO, Inc. BD Biosciences Corning, Inc. EMD Millipore Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version of Adobe Acrobat Reader is required to view the

    0 0
  • 03/31/14--22:00: High Throughput Screening
  • High Throughput Screening This report gives an insight into High Throughput Screening (HTS) technologies, tools and services. The report covers HTS technologies including Ultra High Throughput Screening, High Content Screening, Bioinformatics and Lab-on-a-Chip/Microfluidics. The study includes estimates and projections for the total global HTS market. The market covered for Microfluidics and Bioinformatics pertains to the applications of HTS. Projections and estimates are also illustrated by region, by technology and by product segment. The report serves as a guide to HTS industry, covering more than 600 companies engaged in HTS studies/screening, products and services. Business profiles of 43 major global companies are discussed. Major Contract Research Organizations serving HTS industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered. Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliances between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help in managing and analyzing the

    0 0

    Biopharmaceutical and Vaccine Production Markets   Though biotechnology has created many new therapies and vaccines – including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders – there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently.   Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production.  It includes the following useful information for business planning: •             Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs •             Vaccine Production Estimates  •             Trend Discussion •             Production Methods •             The Competitive Environment, including Contract Manufacturing and Outsourcing •             Regulation of the Market •             Company Profiles   The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical

    0 0

    Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019 Over the years, the cell line development market has witnessed various technological advancements in order to cater to the growing demand for stable and high-yielding cell lines. These advancements have led to growth in a number of applications of cell lines such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery. Cell line development media and reagents account for the largest share in the global cell line development market, as they have numerous applications in areas such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery. The reagents segment accounted for the maximum share of the cell line development media and reagents market. The bioproduction segment accounted for the largest share of the cell line development application market, as cell lines are extensively used in diagnostics, vaccine production, and in manufacturing of recombinant protein therapeutics. North America accounted for the largest share of the global cell line development market, followed by Europe, Asia, and the

older | 1 | 2 | 3 | (Page 4) | 5 | 6 | .... | 17 | newer